Filtered By:
Cancer: Cancer
Therapy: Stem Cell Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 98 results found since Jan 2013.
A new era of macrophage-based cell therapy
Experimental & Molecular Medicine, Published online: 01 September 2023; doi:10.1038/s12276-023-01068-zTreating disease with the white blood cells called macrophages, in some cases genetically modified, could become an effective clinical option for a range of diseases. Macrophages are cells of the innate (non-specific) immune system that can destroy diseased cells or damaging materials. They can also enhance tissue repair by releasing growth factors and anti-inflammatory molecules. Seung Hyeok Seok and colleagues at Seoul National University in South Korea review the laboratory research and clinical trials that are inve...
Source: Experimental and Molecular Medicine - September 1, 2023 Category: Molecular Biology Authors: Yi Rang Na Sang Wha Kim Seung Hyeok Seok Source Type: research
Clonal Hematopoiesis and the Heart: a Toxic Relationship
Curr Oncol Rep. 2023 Mar 15. doi: 10.1007/s11912-023-01398-1. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Clonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes.RECENT FINDINGS: A combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atheroscle...
Source: Atherosclerosis - March 15, 2023 Category: Cardiology Authors: Jeffrey L Jensen Saumya Easaw Travis Anderson Yash Varma Jiandong Zhang Brian C Jensen Catherine C Coombs Source Type: research
Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process
Eur J Med Res. 2022 Nov 4;27(1):232. doi: 10.1186/s40001-022-00833-6.ABSTRACTAngiogenesis is a vital biological process involving blood vessels forming from pre-existing vascular systems. This process contributes to various physiological activities, including embryonic development, hair growth, ovulation, menstruation, and the repair and regeneration of damaged tissue. On the other hand, it is essential in treating a wide range of pathological diseases, such as cardiovascular and ischemic diseases, rheumatoid arthritis, malignancies, ophthalmic and retinal diseases, and other chronic conditions. These diseases and disorder...
Source: Cell Research - November 5, 2022 Category: Cytology Authors: Ahmad Hoseinzadeh Hamed Ghoddusi Johari Mohammad Hossein Anbardar Lobat Tayebi Ehsan Vafa Milad Abbasi Ahmad Vaez Ali Golchin Ali Mohammad Amani Ali Jangjou Source Type: research
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Genotype and Phenotype of Adenosine Deaminase 2 Deficiency: a Report from Saudi Arabia
AbstractAdenosine deaminase 2 deficiency (DADA2), a rare and potentially fatal systemic autoinflammatory disease, is characterized by low or lack of ADA2 activity due toADA2 mutations. DADA2 symptoms are variable and include vasculitis, immunodeficiency, and cytopenia. Minimal data are available from Saudi Arabia. This retrospective study conducted at seven major tertiary medical centers examined the phenotypic and genotypic variabilities, clinical and diagnostic findings, and treatment outcomes among 20 Saudi patients with DADA2 from 14 families. The median age of the study cohort was 9.5 years (4–26 years). The clin...
Source: Journal of Clinical Immunology - October 14, 2022 Category: Allergy & Immunology Source Type: research
Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases
Vasa. 2022 Oct 6. doi: 10.1024/0301-1526/a001031. Online ahead of print.ABSTRACT Vascular adhesion protein-1 (VAP-1) also known as amino oxidase copper containing 3 (AOC3) is a pro-inflammatory and versatile molecule with adhesive and enzymatic properties. VAP-1 is a primary amine oxidase belonging to the semicarbazide-sensitive amine oxidase (SSAO) family, which catalyzes the oxidation of primary amines leading to the production of ammonium, formaldehyde, methylglyoxal, and hydrogen peroxide. VAP-1 is mainly expressed by endothelial cells, smooth muscle cells, adipocytes and pericytes. It is involved in a repertoire of bi...
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - October 6, 2022 Category: Surgery Authors: Marianna Danielli Roisin Clare Thomas Lauren Marie Quinn Bee Kang Tan Source Type: research
